AERIE PHARMACEUTICALS INC
AERIE PHARMACEUTICALS INC (AERI): 8 pipeline candidates · ~54 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
54.1 months
D/E -3.29 · 0% dilution
Lead: Approved
8 candidates
N/A
N/A
A transparent, data-derived signal for AERIE PHARMACEUTICALS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$54.1M
Quarterly Burn
$11.4M
Runway
54.1 mo
Revenue
$36.1M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| 0.003% ar-15512 | Phase 3 |
| ar-1105 | Phase 2 |
| ar-14034 sr | Preclinical |
| ar-15512 | Phase 3 |
| ar-15512 vehicle | Phase 3 |
| ibuprofen | Approved |
| rhopressa | Approved |
| rocklatan | Approved |
Frequently asked questions
How many drug candidates are in AERIE PHARMACEUTICALS INC's pipeline?
AERIE PHARMACEUTICALS INC (AERI) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is AERIE PHARMACEUTICALS INC's lead drug candidate?
AERIE PHARMACEUTICALS INC's most advanced tracked candidate is 0.003% ar-15512 (Phase 3) for Dry Eye Disease.
What is AERIE PHARMACEUTICALS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, AERIE PHARMACEUTICALS INC has approximately 54.1 months of cash runway.
Who is the CEO of AERIE PHARMACEUTICALS INC?
Emperor Boulevard is the chief executive officer of AERIE PHARMACEUTICALS INC (AERI).
Get the full picture on AERIE PHARMACEUTICALS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.